PubMed Health⌕ Search

Biomedical subjects

C De Traversay

Publications and source records attributed to C De Traversay.

2 recordsLinked to original sources

Applications of advanced oxidation processes: present and future.

The use of advanced oxidation processes (AOPs) to remove pollutants in various water treatment applications has been the subject of study for around 30 years. Most of the available processes (Fenton reagent, O3 under basic conditions, O3/H2O2, O3/UV, O3/solid catalyst, H2O2/M(n+), H2O2/UV, photo-assisted Fenton, H2O2/solid catalyst, H2O2/NaClO, TiO2/UV etc.) have been investigated in depth and a considerable body of knowledge has been built up about the reactivity of many pollutants. Various industrial applications have been developed, including ones for ground remediation (TCE, PCE), the removal of pesticides from drinking water, the removal of formaldehyde and phenol from industrial waste water and a reduction in COD from industrial waste water. The development of such AOP applications has been stimulated by increasingly stringent regulations, the pollution of water resources through agricultural and industrial activities and the requirement that industry meet effluent discharge standards. Nevertheless, it is difficult to obtain an accurate picture of the use of AOPs and its exact position in the range of water treatment processes has not been determined to date. The purpose of this overview is to discuss those processes and provide an indication of future trends.

Hydrogen Peroxide↗

Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha.

BACKGROUND/AIMS: The aim of this study was to evaluate the changes in histological lesions and serum N-terminal peptide of type III procollagen (PIIINP) and hyaluronate (HA) levels in virologic non-responder patients treated by Interferon alpha (IFNalpha). METHODS: We enrolled 183 patients treated by IFNalpha and 56 controls, all with paired biopsy specimens. Yearly liver fibrosis progression was estimated before and during a follow-up of 1 year. RESULTS: By contrast to sustained responders, non-responders (n = 105) did not achieve improvement of histological scores after therapy. Their yearly fibrosis progression rate was similar before and during follow-up (0.18, 95%CI: 0.16-0.20, vs 0.26 (95%CI: 0.12-0.40) fibrosis units/year, NS), and was not different in controls (0.17, 95%CI: 0.06-0.27). The levels of PIIINP and hyaluronate (HA) remained unchanged during follow-up. Histological improvement was observed for the second biopsy in 25% of non-responders, but also in 23% of controls. This improvement was not correlated with decrease of ALT level, viral load, PIIINP, or HA. CONCLUSIONS: Our results suggest that IFNalpha therapy is unable to decrease PIIINP or HA levels and cannot improve the histological outcome in virologic non-responder patients. The histological improvement observed in a subset of patients may be linked to sample fluctuation or lack of reproducibility of histological scores.

Adult↗